[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research advances in radiation-induced lung injury and Th1/Th2 imbalance
Cheng Jing,Yao Ye,Xie Conghua
Department of Radiation and Medical Oncology,Zhongnan Hospital,Wuhan University,Hubei Key Laboratory of Tumor Biological Behaviors,Zhongnan Hospital,Wuhan University,Wuhan 430071,China
Abstract Normal lung tissues are inevitably exposed to X-ray in thoracic radiotherapy, causing radiation-induced lung injury (RILI). The main pathological manifestations include the accumulation of inflammatory cells, release of cytokines, accumulation and proliferation of fibroblasts, and excessive deposition of alveolar interstitial collagen in the irradiated region. RILI severely affects the treatment compliance and quality of life and even threatens the life in the patients receiving radiotherapy. In recent years, numerous studies have found that Th1/Th2 imbalance is closely associated with the development and progression of RILI, and the cytokine network plays an executive role in the progression of RILI. Therefore, restoring the Th1/Th2 balance in vivo may provide a new way to prevent and treat RILI.
Cheng Jing,Yao Ye,Xie Conghua. Research advances in radiation-induced lung injury and Th1/Th2 imbalance[J]. Chinese Journal of Radiation Oncology, 2017, 26(6): 706-710.
Cheng Jing,Yao Ye,Xie Conghua. Research advances in radiation-induced lung injury and Th1/Th2 imbalance[J]. Chinese Journal of Radiation Oncology, 2017, 26(6): 706-710.
[1] Jenkins P, Welsh A.Computed tomography appearance of early radiation injury to the lung:correlation with clinical and dosimetric factors[J].Int J Radiat Oncol Biol Phys,2011,81(1):97-103.DOI:10.1016/j.ijrobp.2010.05.017. [2] Jenkins P, Watts J.An improved model for predicting radiation pneumonitis incorporating clinical and dosimetric variables[J].Int J Radiat Oncol Biol Phys,2011,80(4):1023-1029.DOI:10.1016/j.ijrobp.2010.03.058. [3] Sekine I,Sumi M,Ito Y,et al. Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients[J].Radiother Oncol,2006,80(1):93-97.DOI:10.1016/j.radonc.2006.06.007. [4] Baumjohann D, Ansel KM.MicroRNA-mediated regulation of T helper cell differentiation and plasticity[J].Nature Rev Immunol,2013,13(9):666-678.DOI:10.1038/nri3494. [5] Choy DF, Hart KM, Borthwick LA, et al. Th2 and Th17 inflammatory pathways are reciprocally regulated in asthma[J].Sci Transl Med,2015,7(301):301ra129.DOI:10.1126/scitranslmed.aab3142. [6] Lukacs NW,Hogaboam C,Chensue SW,et al. Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis[J].Chest,2001,120(1 Suppl):5S-8S.DOI:10.1378/chest.120.1_suppl. S5. [7] Graves PR,Siddiqui F,Anscher MS,et al. Radiation pulmonary toxicity:from mechanisms to management[J].Semin Radiat Oncol,2010,20(3):201-207.DOI:10.1016/j.semradonc.2010.01.010. [8] Wynn TA, Ramalingam TR.Mechanisms of fibrosis:therapeutic translation for fibrotic disease[J].Nat Med,2012,18(7):1028-1040.DOI:10.1038/nm.2807. [9] Bao P,Gao W, Li S,et al. Effect of pretreatment with high-dose ulinastatin in preventing radiation-induced pulmonary injury in rats[J].Eur J Pharmacol,2009,603(1-3):114-119.DOI:10.1016/j.ejphar.2008.12.007. [10] 涂军伟,赵建平.干扰素γ对大鼠肺纤维化转录因子GATA3 的影响[J].温州医学院学报,2013,43(3):175-177.DOI:10.3969/j.issn.1000-2138.2013.03.008. Tu JW, Zhao JP.Effects of interferon gamma on transcription factor GATA3 in rat pulmonary fibrosis[J].J Wenzhou Med Coll,2013,43(3):175-177.DOI:10.3969/j.issn.1000-2138.2013.03.008. [11] Diaz KT,Skaria S,Harris K,et al. Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis[J].J Aerosol Med Pulm Drug Deliv,2012,25(2):79-87.DOI:10.1089/jamp.2011.0919. [12] Sakamoto H, Zhao LH,Jain F, et al. IL-12p40(-/-) mice treated with intratracheal bleomycin exhibit decreased pulmonary inflammation and increased fibrosis[J].Exp Mol Pathol,2002,72(1):1-9.DOI:10.1006/exmp.2001.2409. [13] Li Y,Zhang C,Wu Y,et al. Interleukin-12p35 deletion promotes CD4 T-cell-dependent macrophage differentiation and enhances angiotensinⅡ-Induced cardiac Fibrosis[J].Arterioscler Thromb Vasc Biol,2012,32(7):1662-1674.DOI:10.1161/ATVBAHA.112.249706. [14] Wang H,Hou L,Kwak D.Increasing Regulatory t cells with interleukin-2 and interleukin-2 antibody complexes attenuates lunginflammation and heart failure progression[J].Hypertension,2016,9.pii:DOI:116.07084. [15] Tsuda M, Zhang WC, Yang GX, et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGF-β receptor type Ⅱ mice[J].Hepatology,2013,57(2):806-816.DOI:10.1002/hep.25829. [16] Jang SS, Kim HG, Lee JS, et al. Melatonin reduces X-ray radiation-induced lung injury in mice by modulating oxidative stress and cytokine expression[J].Int J Radiat Biol,2013,89(2):97-105.DOI:10.3109/09553002.2013.734943. [17] Refahi S,Pourissa M, Zirak MR, et al. Modulation expression of tumor necrosis factor α in the radiation-induced lung injury by glycyrrhizic acid[J].J Med Phys,2015,40(2):95-101.DOI:10.4103/0971-6203.158689. [18] Zhao D,Qu H,Guo J, et al. Protective effects of myrtol standardized against radiation-induced lung injury[J].Cell Physiol Biochem,2016,38(2):619-34.DOI:10.1159/000438655. [19] Zhang M,Qian J,Xing X,et al. Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung[J].Clin Cancer Res,2008,14(6):1868-1876.DOI:10.1158/1078-0432.CCR-07-1894. [20] Hill RP,Zaidi A,Mahmood J,et al. Investigations into the role of inflammation in normal tissue response to irradiation[J].Radiother Oncol,2011,101(1):73-79.DOI:10.1016/j.radonc.2011.06.017. [21] Chung EJ,Hudak K, Horton JA,et al. Transforming growth factor alpha is a critical mediator of radiation lung injury[J].Radiat Res,2014,182(3):350-362.DOI:10.1667/RR13625.1. [22] Naworth I,Alsner J, Behlke MA, et al. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNF-α prevents radiation-induced fibrosis[J].Radiother Oncol,2010,97(1):143-148.DOI:10.1016/j.radonc.2010.09.010. [23] Pallai A,Kiss B,Vereb G,et al. Transmembrane TNF-α reverse signaling inhibits lipopolysaccharide-induced proinflammatory cytokine formation in macrophages by inducing TGF-β:therapeutic implications[J].J Immunol,2016,196(3):1146-1157.DOI:10.4049/jimmunol.1501573. [24] Büttner C, Skupin A, Reimann T,et al. Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats:macrophages as a prominent source of interleukin-4[J].Am J Respir Cell Mol Biol.1997,17(3):315-25.DOI:10.1165/ajrcmb.17.3.2279. [25] Huang YJ,Liu W, Liu H,et al. Grape seed pro-anthocyanidins ameliorates radiation-induced lung injury[J].J Cell Mol Med,2014,18(7):1267-1277.DOI:10.1111/jcmm.12276. [26] Huaux F,Liu T, McGarry B,et al. Dual roles of IL-4 in lung injury and fibrosis[J].J Immunol,2003,170(4):2083-2092.DOI:10.4049/jimmunol.170.4.2083. [27] Migliaccio CT,Buford MC,Jessop F,et al. The IL-4Ralpha pathway in macrophages and its potential role in silica-induced pulmonary fibrosis[J].J Leukoc Biol,2008,83(3):630-639.DOI:10.1189/jlb.0807533. [28] Barrett NA,Austen KF.Innate cells and T helper 2 cell immunity in airway inflammation[J].Immunity, 2009,31(3):425-437.DOI:10.1016/j.immuni.2009.08.014. [29] Wynn TA.Fibrotic disease and the T (H)1/T (H)2 paradigm[J].Nat Rev Immunol,2004,4(8):583-594.DOI:10.1038/nri1412. [30] Glimcher LH,Murphy KM.Lineage commitment in the immune system:the T helper lymphocyte grows up[J].Genes Dev,2000,14(14):1693-1711.DOI:10.1101/gad.14.14.1693. [31] Peng H,Sarwar Z.Profibrotic role for interleukin-4 in cardiac remodeling and dysfunction[J].Hypertension,2015,66(3):582-589.DOI:10.1161/HYPERTENSIONAHA.115.05627. [32] Chen Y,Rubin P,Williams J,et al. Circulating IL-6 as a predictor of radiation pneumonitis[J].Int J Radiat Oncol Biol Phys,2001,49(3).pp.641-648.DOI:10.1016/S0360-3016(00)01445-0. [33] Fielding CA,Jones GW, McLoughlin RM,et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation[J].Immunity,2014,40(1):40-50.DOI:10.1016/j.immuni.2013.10.022. [34] Greenhill CJ,Rose-John S,Lissilaa R,et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3[J].J Immunol,2011,186(2):1199-1208.DOI:10.4049/jimmunol.1002971. [35] Pedroza M,Schneider DJ, Karmouty-Quintana H,et al. Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury[J/OL].PLoS One,2011,6(7):e22667.DOI:10.1371/journal.pone.0022667. [36] Beyer C,Huang J.Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages[J].Ann Rheum Dis,2015,74(6):1317-1324.DOI:10.1136/annrheumdis-2013-204401. [37] Klee S,Lehmann M.WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts[J].Sci Rep,2016;6.pii:srep20547.DOI:10.1038/srep20547. [38] Tomoko SF, Mayumi Iwakawa, Etsuko Nakamura,et al. Attenuated lung fibrosis in interleukin 6 knock-out mice after C-ion irradiation to lung[J].J Radiat Res,2011,52(3):270-277.DOI:10.1269/jrr.10094. [39] O’Donoghue R.J., Knight D.A.et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis[J].EMBO Mol Med,2012,4(9):939-951.DOI:10.1002/emmm.201100604. [40] Lucille D,Jérme A, Avouac J,et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis[J].Arthritis Res Ther,2014,16(4):R157.DOI:10.1186/ar4672. [41] O′Reilly S,Cant R, Marzena Ciechomska,et al. Interleukin-6:a new therapeutic target in systemic sclerosis?[J].Clin Transl Immunol,2013,2(4):e4.DOI:10.1038/cti.2013.2. [42] Shimojo N,Hashizume R.Tenascin-C may accelerate cardiac fibrosis by activating macrophages via the integrin αVβ3/nuclear factor-κB/interleukin-6 axis[J].Hypertension,2015,66(4):757-766.DOI:10.1161/HYPERTENSIONAHA.115.06004. [43] Jin Y,Liu R,Xie J.Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model[J].Lab Invest,2013,93(7):801-811.DOI:10.1038/labinvest.2013.64. [44] Moore KW,de Waal Malefyt R,Coffman RL,et al. Interleukin-10 and the interleukin-10 receptor[J].Annu Rev Immunol, 2001, 19(1):683-765.DOI:10.1146/annurev.immunol.19.1.683 [45] Sabat R,Grütz G,Warszawska K,et al. Biology of interleukin-10[J].Cytokine Growth Factor Rev,2010,21(5):331-344.DOI:10.1016/j.cytogfr.2010.09.002. [46] Alhamad EH,Cal JG, Shakoor Z,et al. Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis[J].BMC Med Genet,2013,1(14):66.DOI:10.1186/1471-2350-14-66. [47] Paun A,Kunwar A,Haston CK.Acute adaptive immune response correlates with late radiation-induced pulmonary fibrosis in mice[J].Radiat Oncol,2015, 10(1):p.359.DOI:10.1186/s13014-015-0359-y. [48] Sun L,Louie MC,Vannella KM,et al. New concepts of IL-10-induced lung fibrosis:fibrocyte recruitment and M2[J].Am J Physiol Lung Cell Mol Physiol,2011,300(3):L341-353.DOI:10.1152/ajplung.00122.2010. [49] Hong ZY,Song KH.An experimental model-based exploration of cytokines in ablative radiation-induced lung injury in vivo and in vitro[J].Lung,2015,193(3):409-419.DOI:10.1007/s00408-015-9705-y. [50] Han G,Zhang H,Xie CH,et al. Th2-like immune response in radiation-induced lung fibrosis[J].Oncol Rep,2011,26(2):383-388.DOI:10.3892/or.2011.1300. [51] Huang Y, Liu W, Liu H, et al. Grape seed pro-anthocyanidins ameliorates radiation-induced lung injury[J].J Cell Mol Med,2014,18(7):1267-1277.DOI:10.1111/jcmm.12276. [52] Murray LA, Zhang H, Oak SR,et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in humanized SCID idiopathic pulmonary fibrosis model[J].Am J Respir Cell Mol Biol,2014,50(5):985-994.DOI:10.1165/rcmb.2013-0342OC. [53] Wynn TA.Cellular and molecular mechanisms of fibrosis[J].J Pathol,2008,214(2):pp.199-210.DOI:10.1002/path.2277. [54] Fichtner-Feigl S,Strober W,Kawakami K,et al. IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis[J].Nature Med,2006,12(1):99-106.DOI:10.1038/nm1332. [55] Wick G,Grundtman C, Mayerl C,et al. The immunology of fibrosis[J].Annu Rev Immunol,2013,31(1):107-135.DOI:10.1146/annurev-immunol-032712-095937. [56] Wynn TA.IL-13 effector functions[J].Annu Rev Immunol,2003,21(1):425-456.DOI:10.1146/annurev.immunol.21.120601.141142
2017, Vol. 26 
